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Abstract
Introduction At least four major categories of invasive breast
cancer that are associated with different clinical outcomes have
been identified by gene expression profiling: luminal A, luminal
B, human epidermal growth factor receptor 2 (HER2) and basal-
like. However, the prevalence of these phenotypes among cases
of ductal carcinoma in situ (DCIS) has not been previously
evaluated in detail. The purpose of this study was to compare
the prevalence of these distinct molecular subtypes among
cases of DCIS and invasive breast cancer.
Methods We constructed tissue microarrays (TMAs) from
breast cancers that developed in 2897 women enrolled in the
Nurses' Health Study (1976 to 1996). TMA slides were
immunostained for oestrogen receptor (ER), progesterone
receptor (PR), HER2, cytokeratin 5/6 (CK5/6) and epidermal
growth factor receptor (EGFR). Using these immunostain
results, cases were grouped into molecularly defined subtypes.
Results The prevalence of the distinct molecular phenotypes
differed significantly between DCIS (n = 272) and invasive
breast cancers (n = 2249). The luminal A phenotype was
significantly more frequent among invasive cancers (73.4%)
than among DCIS lesions (62.5%) (p = 0.0002). In contrast,
luminal B and HER2 molecular phenotypes were both more
frequent among DCIS (13.2% and 13.6%, respectively) as
compared with invasive tumours (5.2% and 5.7%, respectively)
(p < 0.0001). The basal-like phenotype was more frequent
among the invasive cancers (10.9%) than DCIS (7.7%),
although this difference was not statistically significant (p =
0.15). High-grade DCIS and invasive tumours were more likely
to be HER2 type and basal-like than low- or intermediate-grade
lesions. Among invasive tumours, basal-like and HER2 type
tumours were more likely to be more than 2 cm in size, high-
grade and have nodal involvement compared with luminal A
tumours.
Conclusion The major molecular phenotypes previously
identified among invasive breast cancers were also identified
among cases of DCIS. However, the prevalence of the luminal
A, luminal B and HER2 phenotypes differed significantly
between DCIS and invasive breast cancers.
Introduction
Recent studies using microarray technology and unsupervised
cluster analysis have provided new insights into the classifica-
tion of invasive breast cancers [1-4]. These studies have
resulted in the identification of several breast cancer sub-
groups that vary in their gene expression signatures and clini-
cal course. The molecularly distinct breast cancer subgroups
identified to date include luminal subtypes A and B (both of
BMI = body mass index; CBCS = Carolina Breast Cancer Study; CK5/6 = cytokeratin 5/6; CI = Confidence interval; DCIS = ductal carcinoma in 
situ; EGFR = epidermal growth factor receptor; ER = oestrogen receptor; HER2 = human epidermal growth factor receptor 2; OR = odds ratio; PMH 
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which are hormone receptor-positive), the HER2 subtype and
a group known as basal-like cancers [1-4].
Immunohistochemical staining of paraffin sections using anti-
body panels has been shown to be a reliable surrogate for
molecular classification of invasive breast cancers as catego-
rised by gene expression profiling studies [4-8]. Antibodies
against oestrogen receptor (ER), progesterone receptor (PR),
human epidermal growth factor receptor 2 (HER2), cytokera-
tin 5/6 (CK5/6) and epidermal growth factor receptor (EGFR)
have been particularly useful for this purpose. In fact, this
approach to molecular classification (that is, using immunos-
taining as a surrogate for expression profiling) is arguably the
most practical approach to phenotyping large numbers of
archived specimens for which fresh tissue is not available for
expression array analysis [9-11]. In addition, application of this
method to archival tissues from existing studies provides the
opportunity to correlate tissue-marker data with long-term
exposures and follow-up data.
While new information regarding the molecular heterogeneity
of invasive cancers is rapidly emerging, far less is known about
the spectrum of molecular phenotypes among cases of ductal
carcinoma in situ (DCIS), the immediate precursor to invasive
breast cancer. In particular, whether or not the same molecular
subtypes identified among invasive breast cancers are also
seen in DCIS has not been widely studied [12-15]. The pur-
pose of the current study, therefore, was to determine in a
large, well-characterised population of women with invasive
breast cancer and DCIS which of the molecular phenotypes
found in invasive cancers are also seen in DCIS and the fre-
quency of the various molecular phenotypes in DCIS relative
to that in invasive breast cancers.
Materials and methods
Study design and population
The Nurses' Health Study was initiated in 1976, with 121,700
US-registered nurses aged between 30 and 55 returning an
initial questionnaire. The cohort has been followed by mailed
questionnaires biennially to update exposure information and
ascertain non-fatal incident diseases. Information on body
mass index (BMI), reproductive history, age at menopause and
postmenopausal hormone use, as well as diagnosis of cancer
and other diseases are updated every two years through ques-
tionnaires. The follow-up rate among this cohort was more
than 90% through 1996.
Breast cancer case confirmation
All women reporting incident diagnoses of cancer were asked
for permission to review their medical records to confirm the
diagnosis and to classify cancers as in situ or invasive, by his-
tological type, size, and presence or absence of metastases.
To identify cases of cancer in non-respondents who died,
death certificates for all deceased participants and medical
records for the incident cancers were obtained. Following
medical record review, 99% of self-reported breast cancers
were confirmed.
Breast cancer tissue block collection
In 1993, we began collecting archived formalin-fixed paraffin-
embedded breast cancer blocks for participants with primary
incident breast cancers over 20 years of follow-up (1976 to
1996). Cases who reported a prevalent cancer including
breast cancer at baseline were excluded from collection. Of
the 5610 patients with breast cancers that were eligible for
block collection, we were unable to obtain any pathology
material for 1858 cases. The primary reason was because they
had been destroyed by the hospital (45%). The majority of
hospitals archive tissue blocks for between five and 10 years,
therefore we were more successful in obtaining more recent
blocks. The year of diagnosis and age at diagnosis were highly
correlated (Spearman correlation = 0.49; p < 0.0001) and the
temporal effect on our collections is evident, not only in the dif-
ferences in age at diagnosis, but also in the frequency of pre-
menopausal breast cancers when comparing the women from
whom we obtained specimens with those for whom we did
not. However, these two groups of women were very similar
with regards to a number of other breast cancer risk factors
and tumour characteristics (Table 1). After taking into account
age and year of diagnosis, the participants whose tumours
were included in the tissue microarrays (TMAs) were very sim-
ilar to those for whom we were unable to obtain tissue blocks.
We obtained pathology samples for 3752 participants. Of
these, 390 specimens were only slides stained with haematox-
ylin and eosin (H&E) and 45 tissue blocks had to be returned
to the lending hospital before construction of the TMAs and
therefore could not be included. A single pathologist (YF)
reviewed H&E sections from eligible cases to confirm the can-
cer diagnosis, classify the cancer according to histological
type and grade (Nottingham), and circle the area from which
the cores for the TMAs would be taken. Pathology review iden-
tified 420 tumour blocks as being unusable for TMA construc-
tion (eg, the block did not contain residual tumour or there was
insufficient tumour in the block). TMAs were constructed in the
Dana Farber Harvard Cancer Center Tissue Microarray Core
Facility, Boston, MA.
Three cores 0.6 mm in diameter were obtained from each
breast cancer sample and inserted into the recipient TMA
blocks. In total, 23 TMA blocks were constructed from 3093
cancers and positive lymph nodes from 2897 participants. We
excluded from the current analysis participants with positive
lymph nodes only (n = 25), lobular carcinoma in situ (n = 31),
in situ carcinomas with both ductal and lobular features (n =
13), and additional rare tumour types including malignant phyl-
lodes tumours, neuroendocrine carcinoma and angiosarcoma
(n = 10). In situ carcinomas with both ductal and lobular fea-
tures were excluded because their ambiguous histological fea-
tures precluded their definitive categorisation as either DCISAvailable online http://breast-cancer-research.com/content/10/4/R67
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Table 1
Comparison of breast cancer risk factors and breast tumour characteristics according to those who were eligible for the study, 
those for whom we received pathology specimens and those who were included in the tissue microarrays, Nurses' Health Study 
(1976 to 1996)
Eligible for TMA (n = 5610) Received pathology specimens (n = 3752) Included in TMA (n = 2897)
Means
Age at diagnosis, y 56.4 57.4 57.5
Age at menarche, y 12.4 12.4 12.4
Age at first birth, y 25.4 25.4 25.3
Age at menopause, y 46.9 47.1 47.1
BMI at age 18, kg/m2 21.0 21.0 21.0
Parity 3.2 3.2 3.2
Alcohol g/week 6.6 6.1 6.2
Frequencies, n (%)
Family history of BC 805 (14.4) 559 (14.9) 409 (14.1)
Nulliparous 430 (7.7) 281 (7.5) 211 (7.3)
Premenopausal 1345 (24.0) 782 (20.8) 600 (20.7)
Prior BBD 2662 (47.5) 1852(49.4) 1360 (47.0)
Current PMH user 1239 (33.8) 884 (34.2) 688 (34.6)
Year of diagnosis
1976 to 1980 517 (9.4) 223 (6.1) 158 (5.6)
1980 to 1985 1066 (19.4) 565 (15.4) 431 (15.2)
1985 to 1990 1678 (30.6) 1152 (31.3) 899 (31.6)
1990 to 1996 2230 (40.6) 1739 (47.3) 1357 (47.7)
Tumour characteristicsa
DCIS 654 (11.7) 443 (11.8) 270 (9.3)
Invasive 4956 (88.3) 3309 (88.2) 2627 (90.7)
Tumour size
Less than 2 cm 3162 (65.6) 2197 (66.7) 1685 (64.9)
More than 2 cm 1656 (34.4) 1098 (33.3) 911 (35.1)
Grade
Well differentiated 319 (15.2) 240 (16.2) 176 (14.7)
Moderately 860 (41.0) 630 (42.4) 515 (43.1)
Poorly 919 (43.8) 615 (41.4) 505 (42.2)
Nodal involvement
No nodes 3931 (70.1) 2684 (71.5) 2006 (69.2)Breast Cancer Research    Vol 10 No 4    Tamimi et al.
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or lobular carcinoma in situ. For participants with both tumour
and lymph node tissue, only the tumour tissue was evaluated
in the current study. If the invasive case was present with
DCIS, the tumour was considered invasive and scored as
such.
Immunohistochemical analysis
We performed immunohistochemical staining for ER, PR,
HER2, CK5/6 and EGFR on 5 μm paraffin sections cut from
the TMA blocks. Immunostains for each marker were per-
formed in a single staining run on a Dako Autostainer (Dako
Corporation). These particular biomarkers were selected for
analysis because they are commonly used as a surrogate to
classify invasive breast cancers according to their molecular
phenotypes [4-8]. Sources and dilutions of the primary anti-
bodies used in this study are listed in Table 2. Immunostaining
was conducted according to established protocols. Appropri-
ate positive and negative controls were included in all staining
runs.
Immunostained TMA slides were evaluated for ER and PR
expression, HER2 protein overexpression and expression of
CK5/6 and EGFR in each core. Tumour cells that showed
nuclear staining for ER or PR were considered ER-positive or
PR-positive respectively, whereas all ER-negative or PR-nega-
tive cases showed complete absence of tumour cell staining.
Of note, low ER-positive or PR-positive (1 to 10% of tumour
cell nuclei staining) and ER-positive or PR-positive (>10% of
tumour cell nuclei staining) were catagorised as a single "pos-
itive" category for the purposes of this analysis. Tumour cells
were considered positive for HER2 protein overexpression
when more than 10% of the cells showed moderate or strong
membrane staining (2+ and 3+). The results of analyses in
which HER2 positivity was defined as 3+ were very similar to
those presented with a definition of 2+ and 3+. Cases were
considered basal CK-positive or EGFR-positive if any cyto-
plasmic and/or membranous staining was detected in the
tumour cells, even if focal. These latter criteria are similar to
those previously used for scoring these markers in invasive
basal-like cancers [4-6].
Classification of molecular phenotype
Immunostained TMA sections were reviewed under a micro-
scope and visually scored for each individual tissue core as
previously described. We classified a case as positive if there
was staining in any of the three cores from that patient and
1 to 3 nodes 904 (16.1) 585 (15.6) 485 (16.7)
4 to 9 nodes 428 (7.6) 268 (7.1) 213 (7.4)
More than 10 nodes 228 (4.1) 140 (3.7) 129 (4.5)
Metastatic 119 (2.1) 75 (2.0) 64 (2.2)
Receptor status
ER+ 2738 (74.5) 1953 (75.2) 1572 (75.3)
PR+ 2083 (61.2) 1518 (61.9) 1235 (62.3)
aTumour characteristics abstracted from medical pathology reports. BC, breast cancer; BBD, benign breast disease; BMI, body mass index; 
DCIS, ductal carcinoma in situ; ER, oestrogen receptor; PMH, postmenopausal hormone; PR, progesterone receptor; TMA, tissue microarrays.
Table 1 (Continued)
Comparison of breast cancer risk factors and breast tumour characteristics according to those who were eligible for the study, 
those for whom we received pathology specimens and those who were included in the tissue microarrays, Nurses' Health Study 
(1976 to 1996)
Table 2
Sources and dilutions of primary antibodies used in this study
Antibody Clone Manufacturer Dilution
ER 1D5 Dako 1:200
PR PgR 636 Dako 1:50
HER2 A0485 (rabbit polyclonal) Dako 1:400
CK5/6 D5/16B4 Dako 1:50
EGFR 2-18C9 Dako pre-diluted (pharmDX kit)
CK5/6, cytokeratin 5/6; EGFR, epidermal growth factor receptor; ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal 
growth factor receptor 2.Available online http://breast-cancer-research.com/content/10/4/R67
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negative if there was no immunostaining present. Cases that
were ER-positive and/or PR-positive and HER2-negative were
classified as luminal A cancers; cases that were ER-positive
and/or PR-positive and HER2-positive were classified as lumi-
nal B cancers; cases that were ER-negative, PR-negative and
HER2-positive were classified as HER2 type; and cases that
were negative for ER, PR and HER2, and positive for CK 5/6
and/or EGFR were categorised as basal-like. Cases that
lacked expression of all five markers were considered "unclas-
sified" or "null".
Statistical analysis
Information on breast cancer risk factors was obtained from
questionnaires completed biennially. Covariate data at the
time of diagnosis were obtained from the questionnaire before
the report of breast cancer diagnosis. Chi-squared tests were
used to evaluate the independence of selected variables
under the null hypothesis. All statistical tests were two-sided
and p < 0.05 was considered statistically significant. Informed
consent was obtained from each participant. This study was
approved by the Committee on the Use of Human Subjects in
Research at Brigham and Women's Hospital.
Results
This analysis population consisted of breast cancers that
developed in women participating in the Nurses' Health Study
after the baseline questionnaire (in 1976) through to the 1996
follow-up cycle and that could be classified into one of five
molecular phenotypes (n = 2521; 272 DCIS and 2249 inva-
sive). Based on immunostaining data from the five markers
used, overall 1820 tumours were classified as luminal A; 152
were luminal B; 165 were HER2; 266 were basal-like; and
118 tumours were unclassifiable (ER-negative/PR-/HER2-
negative/EGFR-negative/CK5/6-negative). An additional 297
cases were excluded because of staining that could not be
evaluated or insufficient tumour tissue in the core of the sam-
ple.
In general, breast cancer risk factors in women with DCIS and
invasive breast cancer were found to be similar (Table 3).
Women with DCIS were slightly younger when they first gave
birth (24.9 vs. 25.4, p = 0.05), were more likely to report a fam-
ily history of breast cancer (19.0 vs 13.3%; p = 0.02) and a
previous benign breast disease (57.0 vs 44.8%; p = 0.0001)
compared with women with invasive breast cancer. As
expected, women with DCIS were more likely to report their
tumour being detected by screening mammography (81.6%)
compared with women with invasive tumours (38.2%).
Compared with invasive tumours, DCIS lesions were more
likely to be HER2-positive (p < 0.0001). The prevalence of the
molecular phenotypes differed significantly between DCIS
and invasive breast cancers (Table 4). Invasive tumours were
significantly more likely than DCIS to be luminal A (p =
0.0002). In contrast, luminal B and HER2 molecular pheno-
types were more frequent among DCIS than among invasive
tumours (p < 0.0001). The basal-like phenotype was more fre-
quent among the invasive tumours than among DCIS, although
this difference was not statistically significant (p = 0.15). How-
ever, when the analysis of invasive tumours was restricted to
infiltrating ductal carcinomas (n = 1550), the frequency of the
basal-like phenotype (14.4%) was significantly higher than
among DCIS (p = 0.005). In an effort to determine if a single
marker was responsible for distinguishing invasive tumours
from DCIS, we examined ER, PR and HER2 status in multivar-
iate analyses. HER2 was the only marker that significantly dis-
tinguished invasive tumours from DCIS (p < 0.0001).
However, in distinguishing infiltrating ductal tumours from
DCIS, ER was also a strong marginally significant predictor (p
= 0.08).
Molecular phenotypes of DCIS and invasive tumours varied
according to the grade of the lesions (Table 5). High-nuclear-
Table 3
Age and age-standardised characteristics of breast cancer 
cases, Nurses' Health Study (1976 to 1996)
Risk factors DCIS
 (n = 272)
Invasive 
(n = 2249)
Means
Age at diagnosis, y 57.9 57.3
Age at menopause, y 45.2 45.5
Age at menarche, y 12.3 12.4
Body mass index at age 18, kg/m2 20.9 21.0
Paritya 3.1 3.2
Age at first birtha, y 24.9 25.4
Alcohol, g/week 5.7 6.3
Frequency, %
Family history of breast cancer 19.0 13.3
Nulliparous 6.9 6.9
Premenopausal at diagnosis 22.4 20.8
Postmenopausal at diagnosis 76.2 77.2
Prior benign breast disease 57.0 44.8
Current postmenopausal hormone useb 37.3 31.9
Molecular Markers, %
ER positive 74.0 77.0
PR positive 59.9 64.4
HER2 positive 27.2 10.9
aAmong parous women only. bAmong postmenopausal women only. 
DCIS, ductal carcinoma in situ; ER, oestrogen receptor; HER2, 
human epidermal growth factor receptor 2; PR, progesterone 
receptor.Breast Cancer Research    Vol 10 No 4    Tamimi et al.
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grade DCIS was significantly more likely than low-grade or
intermediate-grade lesions to be HER2 type (p < 0.0001) and
basal-like (p = 0.009). Similarly, high-grade invasive cancers
were more likely to be HER2 type (p < 0.0001) and basal-like
(p < 0.0001) than low-grade tumours. Results were similar
when the analysis was limited to invasive ductal tumours only.
Among invasive tumours, molecular phenotypes were differen-
tially associated with prognostic factors (Table 6). Compared
with the luminal A subtype, HER2-type tumours were 2.6 (OR
= 2.6, 95%CI 1.8 to 3.9) times as likely to be more than 2 cm
in size, 3.6 times (OR = 3.6, 95%CI 2.1 to 6.3) as likely to be
high grade and twice as likely to have nodal involvement (OR
= 2.1, 95%CI 1.5 to 3.1). Similarly, basal-like tumours were
more likely to be more than 2 cm in size (OR = 2.0, 95% 1.5
to 2.7), high grade (OR = 5.3, 95%CI 3.5 to 8.1) and have
nodal involvement (OR = 1.5, 95%CI 1.3–1.7) when com-
pared with luminal A tumours.
Discussion
In this large case series, we have shown that by using a panel
of five immunostains, DCIS can be classified into five molecu-
larly defined phenotypes that have been described for invasive
breast carcinomas. Furthermore, we have shown that the prev-
alence of the molecularly defined phenotypes differed signifi-
cantly between DCIS and invasive breast cancers. DCIS were
more likely to be of the luminal B and HER2 phenotypes than
invasive tumours. HER2 and basal-like phenotypes were com-
mon among both high-grade DCIS and high-grade invasive
lesions.
These data provide evidence that DCIS and invasive tumours
are both molecularly heterogeneous. Our finding of an
increased prevalence of luminal B and HER2 molecular sub-
types (ie, HER2-positive) in DCIS is consistent with earlier
studies demonstrating a higher prevalence of HER2 protein
overexpression and gene amplification among DCIS than inva-
sive breast cancers [16-19]. The explanation for the higher
prevalence of HER2 overexpression in DCIS compared with
Table 4
Frequency of molecular phenotypes among DCIS and invasive breast cancers, Nurses' Health Study (1976 to 1996)
Immunophenotype DCIS (n = 272) All invasive (n = 2249) Infiltrating ductal, NOS only (n = 1550) p valuea p valueb
n (%) n (%) N (%)
Luminal A 170 (62.5) 1650 (73.4) 1053 (67.9) 0.0002 0.08
Luminal B 36 (13.2) 116 (5.2) 90 (5.8) <0.0001 <0.0001
HER2+ 37 (13.6) 128 (5.7) 107 (6.9) <0.0001 <0.0001
Basal-like 21 (7.7) 245 (10.9) 223 (14.4) 0.15 0.005
Unclassified 8 (2.9) 110 (4.9) 77 (5.0) 0.15 0.14
ap value from Chi-Squared test comparing DCIS to all invasive tumours. bp value from Chi-Squared test comparing DCIS to infiltrating ductal 
tumours. DCIS, ductal carcinoma in situ.
Table 5
Frequency of molecular phenotypes among DCIS and invasive breast cancers according to tumour gradea, Nurses' Health Study 
(1976 to 1996)
Tumour type Luminal A Luminal B Her2 type Basal Unclassified
DCIS
DCIS, low nuclear grade 26 (92.9) 1 (3.6) 0 1 (3.6) 0
DCIS, intermediate grade 109 (79.0) 15 (10.9) 6 (4.4) 6 (4.4) 2 (1.5)
DCIS, high nuclear grade 35 (33.0) 20 (18.9) 31 (29.3) 14 (13.2) 6 (5.7)
Invasive tumours
Well-differentiated 134 (95.7) 2 (1.4) 0 2 (1.4) 2 (1.4)
Moderately differentiated 344 (79.3) 24 (5.5) 21 (4.8) 31 (7.1) 14 (3.2)
Poorly differentiated 252 (56.8) 20 (4.5) 43 (9.7) 99 (22.3) 30(6.8)
aGrade of DCIS and invasive tumours as determined by centralised pathology review. DCIS, ductal carcinoma in situ.Available online http://breast-cancer-research.com/content/10/4/R67
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invasive carcinoma remains unresolved and several possible
explanations have been offered. These include: some HER2-
positive DCIS lose HER2 expression when they progress to
invasive cancers[19]; invasive carcinomas may arise more fre-
quently from HER2-negative DCIS than from HER2-positive
DCIS; there is a bias in mammographically screened popula-
tions toward the detection of DCIS lesions that are HER2-pos-
itive since these lesions are more frequently associated with
comedo necrosis and, in turn, suspicious mammographic
microcalcifications that prompt biopsy than non-high-grade
DCIS lesions. In support of this explanation, previous studies
have shown that screen-detected DCIS is more often due to
the presence of linear branching and coarse granular calcifica-
tions, as well as DCIS of high nuclear grade and HER2 over-
expression than interval DCIS [20,21].
Consistent with previous studies our results indicate that low-
grade invasive cancers are more likely to have the luminal A
phenotype, whereas high-grade invasive carcinomas are more
likely to be HER2-type and basal-like [6]. In addition, both the
HER2 and basal-like tumours were significantly more likely to
be associated with poorer prognostic factors including larger
tumour size, higher grade and nodal involvement. The Carolina
Breast Cancer Study (CBCS) also examined molecular phe-
notypes of invasive tumours classified using the same immu-
nohistochemical markers and categories as used in the
current study [22]. Consistent with our study, Carey and col-
leagues [22] reported that HER2-type tumours (n = 33) were
more likely to be high grade and have nodal involvement and
that basal-like tumours (n = 100) were more likely to be high
grade relative to luminal A tumours. We observed a strong
association between basal-like tumours and nodal involve-
ment, which was not found in the CBCS study. Although infor-
mation on prognostic and tumour characteristics was not
identical between our studies, both support the hypothesis
that immunohistochemical classification of invasive tumours is
associated with breast cancer prognosis.
We demonstrated a similar relationship between grade and
molecular phenotype for DCIS lesions as was observed for
invasive tumours. In particular, HER2-type (84%) and basal-
like (67%) DCIS lesions were significantly more likely to be
high grade than low-grade or intermediate-grade lesions. A
similar distribution of molecular phenotypes of DCIS accord-
ing to grade was reported in the CBCS, with 92% of HER2
DCIS and 84% of basal-like DCIS being high-grade [13].
These data suggest that similar to invasive tumours, molecular
classification of DCIS lesions may be important in identifying
more aggressive lesions. Additional support for this hypothe-
sis comes from a recent case-control study of women with
DCIS, in which 32 women went on to develop subsequent
cancer (cases) and 38 did not develop subsequent disease
(controls) [23]. This study found that eight of eight DCIS
Table 6
Odds ratios (95% confidence interval) of prognostic factors among invasive breast cancers according to molecular phenotype, 
Nurses' Health Study (1976 to 1996)
Tumour type Luminal A Luminal B Her2 type Basal Unclassified
n OR n OR (95%CI) n OR (95%CI) n OR (95%CI) n OR (95%CI)
Tumour sizea,b
≤ 2.0 cm 1025 54 48 107 57
>2.0 cm 537 1.0 (Ref) 55 1.9 (1.3 to 2.8) 68 2.6 (1.8 to 3.9) 119 2.0 (1.5 to 2.7) 44 1.4 (0.9 to 2.1)
Tumour gradea
Low/Intermediate 478 26 21 33 16
High 252 1.0 (Ref) 20 1.4 (0.8 to 2.6) 43 3.6 (2.1 to 6.3) 99 5.3 (3.5 to 8.1) 30 3.4 (1.8 to 6.4)
Nodal statusa,b
No nodes 1103 72 61 145 70
Any nodes 547 1.0 (Ref) 44 1.2 (0.8 to 1.7) 67 2.1 (1.5 to 3.1) 100 1.3 (1.0 to 1.7) 40 1.1 (0.7 to 1.6)
Menopausal status
Postmenopausal 1289 76 97 187 83
Premenopausal 334 1.0 (Ref) 35 1.8 (1.2 to 2.7) 27 1.1 (0.7 to 1.7) 51 1.1 (0.8 to 1.5) 25 1.2 (0.7 to 1.8)
aAdjusted for age (five-year categories). bTumour characteristics abstracted from medical pathology reports. CI, confidence interval; OR, odds 
ratio.Breast Cancer Research    Vol 10 No 4    Tamimi et al.
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cases expressing high levels of both markers of basal-like sub-
type, p16 and Ki67, developed a subsequent tumour [23].
The majority of epidemiological studies have reported very
similar risk factors for DCIS and invasive breast cancer
[16,24]. However, in these epidemiological studies, DCIS and
invasive tumours are often considered together as one end-
point or are considered as two distinct groups without further
classification according to receptor status. Studies consider-
ing invasive breast cancer according to receptor status have
identified risk factors specific for certain phenotypes and not
others [25,26]. It is likely, however, that the impact of several
established risk factors for DCIS and invasive tumours will dif-
fer according to molecularly defined phenotypes. Further iden-
tification of risk factors for the different molecular phenotype
could be of value in risk assessment and prevention.
A limitation of the current study is that we were unable to
obtain tissue blocks from all breast cancers arising in this
cohort. Our success in doing so was highly correlated with
time between diagnosis and initiation of our tissue block col-
lection. Many hospitals destroy paraffin-embedded tissue
blocks after five to 10 years. After taking into account the
effect of age and year of diagnosis, the women for whom we
were able to obtain tumour specimens were very similar to
those for whom we were unable to obtain specimens. The pri-
mary differences were due to the temporal consequences of
the timing of tumour block collection. In addition, the frequency
of receptor status positivity among invasive tumours was very
similar to other populations suggesting that samples included
in this study are representative of the overall US population.
We used immunohistochemical markers as a surrogate to
classify breast cancers into the molecular phenotypes defined
by expression profiles. While the antibody panel we used in
this study has been shown to be a reliable proxy for classifica-
tion of invasive breast cancers categorised by gene expres-
sion [4-8], the correlation is not perfect and there will be some
misclassification of these phenotypes. The molecular pheno-
type categories as defined by the immunohistochemical mark-
ers have been shown to be associated with prognostic
markers and survival consistent with what has been seen with
classification based on RNA expression assays, suggesting
that both methods are capturing distinct subgroups [5,22].
Misclassification of phenotypes may underestimate true differ-
ences between the subtypes.
Because lesions had to be large enough to yield multiple
cores, it is possible that we may have biased our sample
towards larger DCIS lesions. In addition, the frequency of
DCIS lesions that we were unable to evaluate in the TMA for
ER and HER2 staining was 22% and 18%, respectively.
These are higher than what was observed for invasive lesions
(6% and 7%, respectively), suggesting that the ability to
assess DCIS lesions with three replicate cores is less than for
invasive tumours. However, the frequency of molecular pheno-
types observed in our study is very similar to those reported in
the CBCS among DCIS cases (n = 245) [13], suggesting that
the DCIS cases included in our study are representative of
DCIS cases in the US population.
Conclusion
The introduction of widespread mammographic screening has
resulted in a dramatic increase in the diagnosis of DCIS [27].
A better understanding of the progression from DCIS to inva-
sive cancer to avoid over-treatment is an important public
health concern. The HER2 and basal-like molecular pheno-
types are more common among high-grade DCIS lesions.
Because these phenotypes are also associated with poor
prognosis among women with invasive tumours, molecular
characterisation of in situ tumours may help predict which
lesions will progress to invasive tumours. More aggressive
treatments could be targeted to the subset of women with
DCIS lesions at highest risk of progressing to invasive cancer.
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